Oxford BioMedica Plc has announced plans to raise up to £16 million in a combined private share placement and open offer. The proceeds will be used to continue development of its gene therapy technology, particularly in the area of ophthalmology.
NicOx SA, which has shifted its strategy to focus on ophthalmology, is to in-license point-of-care diagnostics from Rapid Pathogen Screening Inc. The agreement, financial terms of which were not disclosed, was announced on 21 June 2012.
Venture capital-backed Heptares Therapeutics Ltd has extended a research collaboration with the UK Medical Research Council that is looking at the structure of G-protein coupled receptors (GPCRs) and other transmembrane proteins.
Bavarian Nordic A/S has received another vaccine contract from the US government, this time to develop candidate vaccine components and technologies for a combined smallpox and Marburg virus vaccine using the company’s vector technology.
Proximagen Group Plc, a 2003 spin-out of King’s College London with an early-stage portfolio of treatments for central nervous system disorders, is to be acquired for up to £356.8 by Upsher-Smith Laboratories Inc of the US.
Newron Pharmaceuticals SpA of Italy is to acquire NeuroNova AB, a privately-owned Swedish company that specialises in neurogenesis and which has early-stage compounds for Parkinson’s disease and amyotrophic lateral sclerosis (ALS).
A preclinical drug combination treatment that is being positioned to treat dyskinesia has received €1.3 million in new funding from two Danish investment groups, SEED Capital and Novo Seeds, a unit of the Novo Nordisk Foundation.
Basilea Pharmaceutica Ltd is to receive £146 million upfront from Stiefel, a unit of GlaxoSmithKline Plc, for an eczema compound. It will use the proceeds to support the development and registration of its candidate antibiotic and antifungal drugs.
GlaxoSmithKline Plc said that it has extended its $13 per share cash offer for Human Genome Sciences Inc until 17.00 Eastern Standard Time on 29 June. The tender offer was previously scheduled to expire at midnight on 7 June.
Erytech Pharma SA has received €6.95 million in grants and credits from the French innovation agency, OSEO, to lead a consortium that will investigate new therapies for the enzymatic treatment of chemotherapy or radiotherapy-resistant cancers.